Inovio Pharmaceuticals (INO)
(Real Time Quote from BATS)
$1.46 USD
+0.05 (3.55%)
Updated Aug 11, 2025 01:00 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
INO 1.46 +0.05(3.55%)
Will INO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for INO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for INO
3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
Earnings Preview: Dianthus Therapeutics, Inc. (DNTH) Q2 Earnings Expected to Decline
INO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Inovio Pharmaceuticals (INO) Expected to Beat Earnings Estimates: Should You Buy?
Inovio Pharmaceuticals (INO) Reports Q1 Loss, Tops Revenue Estimates
Bet on These 5 Top-Ranked Stocks With Rising P/E
Other News for INO
Data Published in The Laryngoscope shows INO-3107 Resulted in Long-Term Surgery Reduction in ...
Inovio announces peer-reviewed data from INO-3107 study
Earnings week ahead: CSCO, PLUG, AMAT, JD, AMC, and more
INOVIO to Report Second Quarter 2025 Financial Results on August 12, 2025 | INO Stock News
BlackRock, Inc. Reduces Stake in Inovio Pharmaceuticals Inc by 76.81%